Trade Names:DepoCyt- Suspension equivalent to 10 mg/mL cytarabine
Cytarabine exhibits cell-phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions, blocking the progression of cells from the G 1 phase to the S-phase.
T max is within 5 h for free cytarabine in both the ventricle and the lumbar sac.
Intracellularly converted to cytarabine-5′-triphosphate (ara-CTP), which is the active metabolite. Metabolism to ara-U (inactive) is primary route of elimination.
ara-U is excreted in the urine. Biphasic elimination; terminal t ½ is 100 to 263 h (12.5 to 75 mg).
Active meningeal infection hypersensitivity to cytarabine or any other ingredient in the formulation.
The dose of liposomal cytarabine is different from the dose of conventional cytarabine.Induction Therapy Adults
Intrathecally 50 mg every 14 days for 2 doses, during weeks 1 and 3.Consolidation Therapy Adults
Intrathecally 50 mg every 14 days for 3 doses, during weeks 5, 7, and 9. Then, give an additional 50 mg dose during week 13.Maintenance Regimen Adults
Intrathecally 50 mg every 28 days for 4 doses, during weeks 17, 21, 25, and 29.Dosage Adjustment for Neurologic Toxicity Adults
Intrathecally If neurologic toxicity occurs, reduce the dose to 25 mg. Discontinue if toxicity persists.Pretreatment Regimen Adults
Intrathecally To reduce the incidence of chemical arachnoiditis, treat all patients with 4 mg dexamethasone orally or IV twice daily for 5 days starting the day of liposomal cytarabine administration. Inject via an intraventricular reservoir or directly into the lumbar sac. The patient should lie flat for at least 1 h after the injection. Do not use in-line filters.
Refrigerate unopened vials; do not freeze. Avoid shaking vials vigorously. Unopened vials are stable at room temperature for up to 72 h.
Coadministration may increase the risk of neurotoxicity.Gentamicin
Gentamicin effectiveness against Klebsiella pneumoniae strains may be decreased.
Because liposomal cytarabine particles are similar in size and appearance to white blood cells, take care in interpreting CSF examinations following liposomal cytarabine administration.
Headache; asthenia; confusion; somnolence; Transient elevations in CSF protein and WBC; encephalopathy; gait disturbance; neurotoxicity; meningismus; paresthesia.
Nausea; vomiting; constipation.
Myelopathy; back pain; pain.
Chemical arachnoiditis syndrome; nausea; vomiting; headache; fever; neck rigidity; neck pain; meningismus; back pain; CSF pleocytosis.
MonitorBone marrow examinations
During induction therapy, perform leukocyte and platelet counts daily. Perform bone marrow examinations frequently after blasts have disappeared from the peripheral blood.Drug-induced marrow depression
Suspend or modify therapy when drug-induced marrow depression results in a platelet count less than 50,000/mm 3 or a polymorphonuclear granulocyte count less than 1,000/mm 3 .
Category D .
Safety and efficacy have not been established.
Cases of anaphylaxis have occurred resulting in acute cardiopulmonary arrest which required resuscitation. This occurred immediately after IV administration.
Patients with renal function impairment may have a higher likelihood of CNS toxicity after high-dose cytarabine. Use the drug with caution and possibly at reduced doses in patients with poor kidney function.
Patients with hepatic function impairment may have a higher likelihood of CNS toxicity after high-dose cytarabine. Use the drug with caution and possibly at reduced doses in patients with poor hepatic function.
A syndrome manifested primarily by nausea, vomiting, headache, and fever has been a common adverse reaction in all studies. If left untreated, chemical arachnoiditis may be fatal. The incidence and severity of chemical arachnoiditis can be reduced by coadministration of dexamethasone.
Liposomal cytarabine particles and white blood cells are similar in appearance and size. Use caution when interpreting CSF examinations after administration of liposomal cytarabine.
Liposomal cytarabine is an irritant and can cause local irritation or phlebitis. Refer to your institution specific protocol.
Viral, bacterial, fungal, parasitic, or saprophytic infections in any location in the body may be associated with the use of cytarabine alone or in combination with other immunosuppressive agents.
If used intrathecally, do not use a diluent with benzyl alcohol.
Anemia, leukopenia, thrombocytopenia, megaloblastosis, and reduced reticulocytes can be expected. The severity of these reactions is dose- and schedule-dependent.
Peripheral motor and sensory neuropathies have occurred.
Enhanced neurotoxicity has been associated with concurrent use of intrathecal cytarabine and other cytotoxic agents administered intrathecally. Monitor neurologic function at baseline and periodically throughout treatment.
Copyright © 2009 Wolters Kluwer Health.